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A commentary on
Tumefactive Demyelinating Lesions as a First Clinical Event: Clinical, Imaging, and Follow-up 
Observations
by Jeong IH, Kim S-H, Hyun J-W, Joung A, Cho H-J, Kim HJ. J Neurol Sci (2015) 358:118–24. 
doi:10.1016/j.jns.2015.08.034
We read with great interest the paper recently published by Jeong and colleagues exploring the long-
term evolution and disease course of patients initially presenting with tumefactive demyelinating 
lesions (TDLs) and describing their clinical and radiographic characteristics. They found that 
most of TDLs evolve into multiple sclerosis (MS) or neuromyelitis optica spectrum disorders 
(NMOSD), albeit a minority of patients remains without a definite diagnosis, even after a careful 
and extensive diagnostic workup (1). The authors underlined that the current understanding of 
the etiology of TDLs should be revaluated upon appraisal of NMOSD because extensive brain 
lesions have been frequently reported as a first manifestation in NMOSD, especially in Asian 
populations (1).
This subject has been matter of debate in the recent years, and several papers have discussed the 
diagnostic challenges associated with the differential diagnosis of brain TDLs (2–6). Despite the 
pathogenesis of TDLs is mainly based, similar to MS, on inflammatory-demyelinating mechanisms, 
they present “tumor-like” radiologic characteristics, such as size greater than 2.0 cm, mass effect, 
and edema, atypical for classic MS lesions. Therefore, the differential diagnosis of TDLs should also 
include brain tumors, even in the presence of typical demyelinating lesions since MS and gliomas 
may, albeit rarely, coexist (7). The evolution of TDLs over time and their response to steroid therapy 
help to define the diagnosis but often postpone the commencement of appropriate treatments (2). 
Remarkably, more invasive investigations, such as brain biopsy, may sometimes be inconclusive or 
even lead to misdiagnosis (5).
Great efforts aimed to overcome these difficulties and to find less invasive and more reliable 
diagnostic tools to allow an early diagnosis of TDLs. Although some radiological characteristics on 
routine magnetic resonance imaging (MRI) such as an open-ring enhancement, T2-hypointense 
rim, peripheral restriction on diffusion-weighted imaging, and venular enhancement are consid-
ered typical for TDLs, they were not found in all cases (1–5). Even the advanced MRI techniques, 
such as MR spectroscopy, led to equivocal results because both normalized choline increase and 
N-acetyl-aspartate decrease were found in variable proportion in both TDLs (3, 4) and gliomas 
(3) with a broad overlap between these diseases. Furthermore, the relative cerebral blood volume 
on dynamic contrast-enhanced MRI, normalized to the respective values of the contralateral 
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hemisphere, has been found higher in gliomas compared to 
TDLs (6), as well as similarly increased in both pathologies (3).
Interestingly, some radiologic findings, such as venular 
enhancement, edema, mass effect, and vessel-like structures 
running through the lesion center, support the relevance of 
venous involvement in TDL pathogenesis. Furthermore, one 
study reported signs of hemorrhage and blood stasis on and 
around the TDL during the venous phase on brain angiography 
suggesting that the presence of multiple venous dilatations can 
help to diagnose TDLs (4). In one well-illustrated case, there 
were innumerable perivenular enhancements perpendicular to 
the lateral ventricles within extensive bihemispheric white matter 
TDLs, showing a parallel temporal evolution (8). These venular 
enhancements are usually attributed to dilated venules draining 
toward distended subependymal veins (4). Enlarged blood vessels 
with surrounding edema and relative axonal preservation were 
observed also at histological examination (3, 5). Moreover, some 
clinical symptoms, more frequent in TDLs than in MS, such as 
encephalopathy, confusion, rapid memory dysfunction, seizures, 
stupor/coma (4, 5), and even increased intracranial pressure 
symptoms (1), are more compatible with venous stasis than with 
localized and well-defined demyelinating lesions.
Inflammatory cell infiltration and demyelination in MS have 
a well-known perivenular distribution involving the smaller 
vessels. When inflammatory processes have a greater intensity 
and extension, they likely determine a markedly slowed venous 
flow with partial thrombosis in larger venules manifesting 
with “tumor-like” characteristics of TDLs. Demyelinating and 
thrombotic diseases of the central nervous system (CNS) share 
common predisposing factors, such as smoking, endothelial 
dysfunction, platelet activation, thrombophilia, and hyper-
homocysteine, all representing prothrombotic conditions (9). 
An increased risk of venous thromboembolism in MS reported 
in epidemiological studies (9) and a correlation between MS 
relapses and prothrombotic factors, such as antiphospholipid 
antibody positivity (10), support the hypothesis that the activa-
tion of coagulation system plays a role in MS pathogenesis (9). 
Indeed, fibrin deposition precedes and regulates the inflamma-
tory demyelination in both experimental allergic encephalomy-
elitis and MS (9). Antiphospholipid positivity is even greater in 
NMOSD than in MS (11), and it should be noted that NMOSD 
usually represent a more severe disease as compared to MS and 
at the same time frequently associate with extensive brain lesions 
similar to TDLs (1). The increased antiphospholipid positivity in 
NMOSD indicates a raised likelihood of thrombotic phenomena 
in this disease, and thus, presumably in TDLs. Finally, the concept 
of thromboinflammation was recently applied also to ischemic 
stroke, defined as a thromboinflammatory disease, connecting 
inflammation and thrombosis through the activation of innate 
immunity (12).
Nevertheless, it is not surprising that venous involvement 
in CNS diseases has been relatively neglected since there are 
several practical difficulties in studying small–medium venous 
vasculature with routinely used MRI sequences (13). In fact, 
only case reports and few reviews have been published on the 
isolated cortical vein thrombosis so far (14), whereas there are 
extensive guidelines on cerebral venous thrombosis of dural 
sinuses and large veins (15). The application of susceptibility 
imaging methods, such as T2-weighted gradient-echo imaging, 
susceptibility-weighted imaging, and quantitative susceptibility 
mapping, look very promising for studying venous structure 
and further researches could use them in order to prove their 
applicability in the differential diagnosis of TDLs. Susceptibility-
weighted imaging is sensitive to susceptibility differences and 
gives improved images of the venous system, by emphasizing 
deoxygenated hemoglobin (13). This allows the definition of 
the anatomic relationships between the venous system and the 
demyelinating lesions. Quantitative susceptibility mapping is 
a recently developed MRI technique that, by using a different 
approach from traditional susceptibility-weighted imaging, is 
able to quantify the tissue susceptibility in each pixel (13). The 
voxel intensity in quantitative susceptibility mapping is propor-
tional to the underlying tissue apparent magnetic susceptibility. 
Interestingly, the quantitative nature of quantitative susceptibility 
mapping makes it an attractive tool for possible follow-up of the 
lesions. We believe that these new advanced MRI techniques may 
also improve our understanding of the pathophysiology of the 
TDLs, thus ameliorating the diagnostic algorithm and warranting 
a more specific treatment.
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